Long-term treatment of depressive syndromes with Psyton
Jellinger, K.; Koeppen, D.; Rössner, M.
Wiener Medizinische Wochenschrift 132(8): 183-188
1982
ISSN/ISBN: 0043-5341 PMID: 6125057 Document Number: 191299
23 patients (in-patients and out-patients) with anxious-depressive symptoms were treated orally with the combination drug Psyton (nomifensine/clobazam) up to 6 months. Significant improvement of both anxiety and depression were observed by both the patients' and physician's assessment, particularly during the first month of treatment. Physical examination and laboratory investigations (weight, pulse rate, blood pressure, EKG, ophthalmology, blood and urine analysis, liver function tests) were not influenced by Psyton. Drug tolerance was good, and side effects observed in 39% of the patients were minimal and mainly occurred within 4 weeks after onset of treatment. There was no tendency to physical drug dependence during treatment and during a one-week placebo phase after discontinuation of Psyton. Hence, a long-term treatment of anxious depressive syndromes with this combination drug appears justified without development of drug dependence.